Phase I data for Blueprint Medicines Corp.'s kinase inhibitor BLU-285 prompted the US FDA to grant a breakthrough therapy designation for the treatment of a small, genetically defined group of patients with gastrointestinal stromal tumors (GIST), which could result in approval based on positive results from the expansion cohort of the early-stage clinical trial.
BLU-285 selectively inhibits the PDGFRα and KIT kinases, but the breakthrough therapy designation only covers the drug's use as a...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)